Pregnancy with multiple sclerosis.
Breastfeeding
Delivery
Disease modifying drugs
Multiple sclerosis
Pregnancy
Journal
Revue neurologique
ISSN: 0035-3787
Titre abrégé: Rev Neurol (Paris)
Pays: France
ID NLM: 2984779R
Informations de publication
Date de publication:
Mar 2021
Mar 2021
Historique:
received:
20
12
2019
revised:
05
05
2020
accepted:
05
05
2020
pubmed:
2
8
2020
medline:
30
7
2021
entrez:
2
8
2020
Statut:
ppublish
Résumé
Multiple sclerosis (MS) is usually diagnosed between twenty and forty years of age, when people often plan to have children. A lot has been said about the effect of pregnancy on the course of MS. The individual factors responsible for the disease modifying effect of pregnancy are not well determined. Having MS neither affects the fertility or the course of pregnancy itself. During pregnancy, many women find that their symptoms stay the same or even improve. Epidural and spinal analgesia appear to be safe and in general are not contraindicated for patients with MS. The management of disease-modifying treatments (DMTs) in pregnancy is a new issue for consideration in the clinical practice. There is limited information available into the safety of DMT use during pregnancy, especially for the most recent ones. In general, discontinuation of DMTs is recommended before conception to minimize risk of fetal harm. Women with very active MS before pregnancy who stop second-line treatments may show an increase in disease activity during pregnancy. Therefore, it might be discussed to maintain patients on DMTs until pregnancy is confirmed, and sometimes throughout pregnancy, to avoid a rebound of disease activity and severe relapses during pregnancy in very active patients.
Identifiants
pubmed: 32736812
pii: S0035-3787(20)30612-3
doi: 10.1016/j.neurol.2020.05.005
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
180-194Informations de copyright
Copyright © 2020 Elsevier Masson SAS. All rights reserved.